Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype

Hepatology

Volumn 63, Issue 6, 2016, Pages 1888-1899

  Matter, Matthias S ^a,b   Marquardt, Jens U ^a,c   Andersen, Jesper B ^a,d   Quintavalle, Cristina ^b   Korokhov, Nikolay ^a   Stauffer, Jim K ^e   Kaji, Kosuke ^a   Decaens, Thomas ^a   Quagliata, Luca ^b   Elloumi, Fathi ^f   Hoang, Tanya ^b   Molinolo, Alfredo ^f   Conner, Elizabeth A ^a   Weber, Achim ^g   Heikenwalder, Mathias ^h,i   Factor, Valentina M ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AKT 1 PROTEIN; BETA CATENIN; CXCL16 CHEMOKINE; FAT DROPLET; GALECTIN 3; NEDD9 PROTEIN; PROTEIN KINASE B; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MORPHOLOGY; CANCER PROGNOSIS; CELL PROLIFERATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; UPREGULATION;

EID: 84978239454     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28487     Document Type: Article

References (30)

1. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149:1226–1239.
2. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883–899.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–1127.
4. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology—analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711–719.
5. Preisegger KH, Factor VM, Fuchsbichler A, Stumptner C, Denk H, Thorgeirsson SS. Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab Invest 1999;79:103–109.
6. Recknagel RO, Glende EA Jr, Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther 1989;43:139–154.
7. Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, et al. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology 2012;55:833–845.
8. Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, et al. Coactivation of AKT and beta-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res 2011;71:2718–2727.
9. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012;122:2911–2915.
10. Thoolen B, Maronpot RR, Harada T, Nyska A, Rousseaux C, Nolte T, et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol 2010;38:5S–81S.
11. Ward JM. Morphology of hepatocellular neoplasms in B6C3F1 mice. Cancer Lett 1980;9:319–325.
12. Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res 2012;72:3546–3556.
13. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008;38:1098–1111.
14. Lu P, Wang ZP, Dang Z, Zheng ZG, Li X, Zhou L, et al. Expression of NEDD9 in hepatocellular carcinoma and its clinical significance. Oncol Rep 2015;33:2375–2383.
15. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, et al. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest 2011;121:2102–2110.
16. Gabitova L, Gorin A, Astsaturov I. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 2014;20:28–34.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545–15550.
18. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667–676.
19. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995–2004.
20. Wellek S. Testing Stastistical Hypothesis of Equivalence. Boca Raton, FL: Chapman & Hall/CRC Press; 2003.
21. Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 2010;9:74.
22. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99–111.
23. Uehara T, Ainslie GR, Kutanzi K, Pogribny IP, Muskhelishvili L, Izawa T, et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci 2013;132:53–63.
24. Beer S, Komatsubara K, Bellovin DI, Kurobe M, Sylvester K, Felsher DW. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS One 2008;3:e2493.
25. Serizawa N, Tian J, Fukada H, Baghy K, Scott F, Chen X, et al. Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Lab Invest 2015;95:1145–1156.
26. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060–5065.
27. Vansaun MN, Mendonsa AM, Lee Gorden D. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. PLoS One 2013;8:e73054.
28. Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 2013;57:610–624.
29. Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, et al. Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012;122:586–599.
30. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565–1570.